Oral Antidiabetic Drugs

Non-insulin pharmacotherapy of type 2 diabetes mellitus (T2DM) is one of the most rapidly evolving and most-tested areas in NEET PG pharmacology. The trend has shifted decisively from "sugar-lowering" to outcome-driven therapy — cardiovascular (CV) and renal protection now dictate drug choice as much as HbA1c reduction. This note organises every class by mechanism, then layers on the high-yield contraindications, hypoglycaemia stratification, and combination logic examiners love.

The big picture — classification by mechanism

Oral antidiabetic drugs (OADs) act on four broad nodes: the liver (gluconeogenesis), the beta cell (insulin secretion), peripheral tissue (insulin sensitivity), and the gut/kidney (glucose handling). Newer injectables (GLP-1 RAs) and the orally active semaglutide blur the "oral" boundary but are conceptually grouped with incretin therapy.

Class	Prototype	Primary mechanism	Site
Biguanide	Metformin	↑ AMPK → ↓ hepatic gluconeogenesis	Liver
Sulfonylureas (SU)	Glimepiride, glipizide, glibenclamide	Close KATP channel → insulin secretion	Beta cell
Meglitinides	Repaglinide, nateglinide	Close KATP (short-acting)	Beta cell
Thiazolidinediones (TZD)	Pioglitazone	PPAR-γ agonist → ↑ insulin sensitivity	Adipose/muscle
α-Glucosidase inhibitors	Acarbose, miglitol, voglibose	Inhibit intestinal α-glucosidase	Gut
DPP-4 inhibitors (gliptins)	Sitagliptin, vildagliptin, linagliptin	↑ endogenous incretins	Gut/beta cell
GLP-1 receptor agonists	Liraglutide, semaglutide, dulaglutide	Incretin mimetic	Beta cell/brain/gut
SGLT2 inhibitors (gliflozins)	Empagliflozin, dapagliflozin, canagliflozin	Block proximal tubule glucose reabsorption	Kidney

High-yield: Only two classes intrinsically cause hypoglycaemia when used alone — sulfonylureas and meglitinides (insulin secretagogues). Metformin, TZDs, gliptins, GLP-1 RAs, SGLT2 inhibitors and α-glucosidase inhibitors are essentially euglycaemic agents (no hypoglycaemia as monotherapy).

Metformin — the undisputed first line

Mechanism: Activates AMP-activated protein kinase (AMPK) by inhibiting mitochondrial complex I (glycerophosphate shuttle) → fall in cellular energy charge → AMPK activation. Net effects: suppression of hepatic gluconeogenesis (dominant action), reduced intestinal glucose absorption, and increased peripheral glucose uptake. It is an insulin sensitiser, not a secretagogue, so no hypoglycaemia and no weight gain (mildly weight-favourable).

Pharmacokinetics: Not metabolised; excreted unchanged by the kidney. This explains accumulation and lactic acidosis risk in renal failure.

Adverse effects:

• GI intolerance (diarrhoea, metallic taste) — commonest; mitigated by titration and extended-release form.
• Vitamin B12 malabsorption with long-term use → macrocytic anaemia/neuropathy.
• Lactic acidosis — rare but feared; type B lactic acidosis.

High-yield: Stop metformin when eGFR < 30 mL/min/1.73 m² (absolute contraindication). Between 30–45, do not initiate and halve the dose if continuing. Withhold around iodinated contrast and major surgery (lactic acidosis risk with acute renal hypoperfusion).

Other contraindications: hepatic failure, decompensated heart failure/hypoxic states, alcoholism, sepsis. Metformin is also first-line in PCOS and used in prediabetes prevention.

Sulfonylureas — the K_ATP channel story

Mechanism flow: SU binds SUR1 subunit of the K_ATP channel on the beta cell → channel closure → membrane depolarisation → opening of voltage-gated Ca²⁺ channels → Ca²⁺ influx → insulin exocytosis.

SU bind SUR1 → K_ATP closes → depolarisation → Ca²⁺ influx → insulin release

This is glucose-independent secretion, which is exactly why SUs cause hypoglycaemia and weight gain.

Generation	Examples	Notes
First	Tolbutamide, chlorpropamide	Obsolete; chlorpropamide → SIADH, disulfiram-like reaction, longest acting
Second	Glibenclamide (glyburide), glipizide, gliclazide	Glibenclamide → highest hypoglycaemia risk (active renally-cleared metabolite)
Third	Glimepiride	Once-daily, lower hypoglycaemia, possible CV-neutral profile

High-yield: Glibenclamide (glyburide) carries the highest risk of severe, prolonged hypoglycaemia, especially in the elderly and CKD — avoid it. Glipizide is preferred in renal impairment (inactive metabolites, short half-life). Gliclazide has the most favourable CV/hypoglycaemia profile among SUs.

SUs require functioning beta cells (ineffective in T1DM/late T2DM). Avoid in sulfa allergy. Sulfonylurea-induced hypoglycaemia is treated with glucose; in refractory cases give octreotide (suppresses the ongoing insulin secretion) — a classic toxicology MCQ.

Meglitinides (repaglinide, nateglinide) bind a different site on SUR1, act rapidly and briefly — taken just before meals to control post-prandial glucose; useful in CKD (repaglinide is hepatically cleared) and in sulfa allergy.

Thiazolidinediones — PPAR-γ agonism

Mechanism: Agonist at peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear transcription factor in adipocytes → increased insulin sensitivity, redistribution of fat, ↑ adiponectin. Pioglitazone is the only one in wide use (rosiglitazone withdrawn/restricted for CV concerns).

Adverse effects (heavily tested):

• Fluid retention/oedema → precipitates/worsens heart failure (contraindicated in NYHA III–IV).
• Weight gain.
• Bone fractures (distal limb, in women) — reduced bone density.
• Bladder cancer association with pioglitazone (avoid in active/history of bladder cancer, unexplained haematuria).
• Hepatotoxicity (legacy concern from troglitazone — monitor LFTs).

High-yield: TZDs take weeks for full effect (genomic action) and are contraindicated in heart failure. Benefit: useful in NAFLD/NASH and marked insulin resistance; no hypoglycaemia as monotherapy.

Incretin-based therapy — DPP-4 inhibitors and GLP-1 receptor agonists

The incretin effect: oral glucose evokes far more insulin than equivalent IV glucose because gut hormones GLP-1 and GIP amplify glucose-dependent insulin secretion. GLP-1 also suppresses glucagon, delays gastric emptying, and promotes satiety. Both are degraded by dipeptidyl peptidase-4 (DPP-4).

DPP-4 inhibitors (gliptins): Block DPP-4 → raise endogenous GLP-1/GIP. Weight-neutral, no hypoglycaemia, well tolerated orally. Linagliptin is not renally cleared (biliary excretion) → preferred in CKD without dose adjustment. Caution: pancreatitis; saxagliptin/alogliptin linked to heart-failure hospitalisation (SAVOR-TIMI). Modest HbA1c reduction (~0.5–0.8%).

GLP-1 receptor agonists: Resistant-to-DPP-4 incretin mimetics. Potent HbA1c reduction with weight loss and glucose-dependent secretion (low hypoglycaemia).

Feature	DPP-4 inhibitors	GLP-1 receptor agonists
Route	Oral	Mostly SC (oral semaglutide exists)
Effect on weight	Neutral	Loss (marked)
HbA1c reduction	Modest	Large
CV benefit	Neutral	Proven (liraglutide, semaglutide, dulaglutide)
Key AEs	Pancreatitis, arthralgia	Nausea/vomiting, pancreatitis, gallstones
Contraindication	—	Medullary thyroid carcinoma / MEN-2 (rodent C-cell tumours)

High-yield: GLP-1 RAs (e.g. semaglutide, liraglutide) give proven CV risk reduction and weight loss — preferred when atherosclerotic CVD or obesity dominates. Tirzepatide is a dual GIP/GLP-1 agonist with the greatest weight loss. Contraindicated with personal/family history of medullary thyroid carcinoma or MEN-2A.

SGLT2 inhibitors — the outcome game-changers

Mechanism: Block sodium-glucose cotransporter-2 in the S1 segment of the proximal convoluted tubule, which normally reabsorbs ~90% of filtered glucose. Result: glucosuria → lowered plasma glucose independent of insulin, plus osmotic diuresis, natriuresis, weight loss, and BP reduction.

Why they win MCQs: Landmark trials (EMPA-REG, CANVAS, DAPA-HF, DAPA-CKD, CREDENCE) showed reduced heart-failure hospitalisation, slowed CKD progression, and CV mortality benefit — benefits that extend to non-diabetics with HFrEF/HFpEF and CKD.

Adverse effects:

• Genital mycotic infections / UTIs (glucosuria) — commonest.
• Euglycaemic diabetic ketoacidosis (euDKA) — DKA with near-normal glucose; suspect on sick days, peri-operatively, low-carb states. Withhold before surgery.
• Volume depletion/hypotension; canagliflozin → ↑ amputation and fracture risk (CANVAS).
• Fournier's gangrene (rare necrotising fasciitis of perineum).

High-yield: Choose an SGLT2 inhibitor when heart failure or chronic kidney disease coexists with T2DM — and a GLP-1 RA when ASCVD/obesity dominates. Both can be used regardless of metformin, and both are favoured by current outcome-based guidelines as preferred second agents.

α-Glucosidase inhibitors

Acarbose, voglibose, miglitol competitively inhibit brush-border α-glucosidase, delaying disaccharide breakdown → blunted post-prandial hyperglycaemia. No systemic hypoglycaemia.

• AE: flatulence, bloating, diarrhoea (undigested carbohydrate fermentation).
• Treat hypoglycaemia (if patient also on SU/insulin) with oral glucose/dextrose, NOT sucrose — because sucrose breakdown is blocked. A favourite trick question.

A rational stepwise approach (exam framework)

1. Lifestyle + metformin at diagnosis (unless contraindicated).
2. Assess comorbidity-driven second agent:
   • ASCVD / high CV risk → GLP-1 RA (or SGLT2i).
   • Heart failure → SGLT2 inhibitor.
   • CKD (albuminuria/↓eGFR) → SGLT2 inhibitor (GLP-1 RA if SGLT2i unsuitable).
3. If cost is dominant / minimise hypoglycaemia → SU or pioglitazone; if minimise weight gain → DPP-4i, GLP-1 RA, SGLT2i.
4. Persistent hyperglycaemia → add insulin (basal first).

Diagnosis → comorbidity assessment → mechanism-matched add-on → escalate to insulin

Complications and contraindications at a glance

Drug class	Hypoglycaemia	Weight	Key contraindication
Metformin	No	Neutral/↓	eGFR < 30, lactic acidosis states
Sulfonylureas	Yes	↑	Sulfa allergy, severe CKD (glibenclamide)
TZD (pioglitazone)	No	↑	Heart failure, bladder cancer
DPP-4 inhibitors	No	Neutral	Pancreatitis history; HF (saxagliptin)
GLP-1 RAs	No (low)	↓	Medullary thyroid Ca / MEN-2
SGLT2 inhibitors	No	↓	Recurrent euDKA, recurrent genital infections
α-glucosidase inh.	No	Neutral	IBD, malabsorption

Key differentials / "which drug?" discriminators

• No hypoglycaemia + lactic acidosis risk + B12 deficiency → Metformin.
• Weight loss + cardioprotection + thyroid Ca contraindication → GLP-1 RA.
• Glucosuria + HF/CKD benefit + euglycaemic DKA → SGLT2 inhibitor.
• Oedema + fractures + bladder cancer + HF worsening → Pioglitazone.
• Hypoglycaemia + weight gain + treat overdose with octreotide → Sulfonylurea.
• Flatulence + post-prandial control + treat hypoglycaemia with glucose not sucrose → Acarbose.

Recently asked / exam angle

• Mechanism matching is perennial: AMPK → metformin, K_ATP/SUR1 → sulfonylurea, PPAR-γ → pioglitazone, SGLT2 (proximal tubule) → gliflozins, DPP-4 → gliptins.
• SGLT2 inhibitors and euglycaemic DKA — recurring single-best-answer stem (DKA with glucose ~200 mg/dL).
• Drug of choice for T2DM with heart failure → SGLT2 inhibitor; with established ASCVD → GLP-1 RA. Increasingly favoured over the older "metformin then SU" reflex.
• Octreotide for refractory sulfonylurea-induced hypoglycaemia.
• Linagliptin preferred in renal impairment (no dose adjustment); glipizide/repaglinide preferred secretagogues in CKD.
• Pioglitazone contraindicated in heart failure; bladder cancer association.
• Acarbose — manage hypoglycaemia with glucose, not sucrose.
• Metformin and B12 deficiency; metformin stop threshold eGFR < 30.
• Tirzepatide as a dual GIP/GLP-1 agonist — newer, high-yield for weight loss.

High-yield mnemonic: Drugs that lose weight = the "SG" pair — SGLT2 inhibitors and GLP-1 RAs (also metformin neutral-to-down). Drugs that gain weight = SU, meglitinides, TZD, insulin.

Rapid revision

1. Metformin = first-line; activates AMPK, suppresses hepatic gluconeogenesis, no hypoglycaemia, watch lactic acidosis and B12 deficiency, stop at eGFR < 30.
2. Sulfonylureas close K_ATP (SUR1) → insulin release; cause hypoglycaemia and weight gain; glibenclamide worst, glipizide/gliclazide safer.
3. Refractory SU hypoglycaemia → octreotide.
4. Pioglitazone = PPAR-γ agonist; contraindicated in heart failure; causes oedema, fractures, bladder cancer risk; useful in NAFLD.
5. DPP-4 inhibitors raise endogenous incretins; weight-neutral, no hypoglycaemia; linagliptin safe in CKD; saxagliptin → HF risk.
6. GLP-1 RAs (semaglutide, liraglutide) → weight loss + proven CV benefit; contraindicated in medullary thyroid Ca/MEN-2; AE nausea, pancreatitis.
7. SGLT2 inhibitors block proximal tubule glucose reabsorption → HF and CKD protection; cause genital infections and euglycaemic DKA.
8. Acarbose blunts post-prandial glucose; treat coincident hypoglycaemia with glucose, not sucrose.
9. HF → SGLT2i; ASCVD → GLP-1 RA; CKD → SGLT2i are the modern drug-of-choice rules.
10. Only secretagogues (SU + meglitinides) and insulin cause hypoglycaemia; all others are essentially euglycaemic.
11. Tirzepatide = dual GIP/GLP-1 agonist, greatest weight reduction.
12. Withhold metformin and SGLT2i around contrast/surgery (lactic acidosis, euDKA respectively).